First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias - Concepedia

Concepedia

Publication | Open Access

First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias

DOI Full Paper Access

15

Citations

40

References

2020

Year

C. J. G. Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Samantha Prins, Thalia F. van der Doef, Giles A. Brown, Alastair Brown, Miles Congreve,

British Journal of Clinical Pharmacology

Abstract

HTL0018318 showed well-characterized pharmacokinetics and following single doses were generally well tolerated in the dose range studied. These provide encouraging data in support of the development for HTL0018318 for Alzheimer's disease and other dementias.

References

	Year	Citations

Page 1